Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026

Contributed by: Business Wire

Tags

Biotechnology

Pharmaceutical

General Health

Health

FDA

Infectious Diseases

Clinical Trials

Other Health

Phase III ReSPECT Results

More Like This

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients

Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)

Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults1

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

New global guideline published on managing fungal infections caused by Candida

New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome